[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.207.116. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,746
Citations 0
The Best of the Best
July 2012

Top-Accessed Article: Severe Hidradenitis Suppurativa Treated With Infliximab Infusion

Arch Dermatol. 2012;148(7):802. doi:10.1001/archdermatol.2012.542

Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139(12):1540-1542.

Hidradenitis suppurativa (HS) remains one of the most challenging and humiliating diseases in dermatology. It occurs in 1% to 2% of the population and is categorized into 3 stages. The third stage has very few treatment options, and the most successful to date has been infliximab.1 Since the article by Adams and colleagues, there have been 8 studies looking at the use of infliximab for HS. One of the few double-blind placebo-controlled studies published for any treatment option for HS showed a 50% improvement compared with placebo.2 In my experience, inflixmab infusion is not a cure, but it does offer significant improvement in pain, swelling, and drainage. It also may offer insight into the mechanism of this disabling condition.

From October 2010 to August 2011, this article was accessed 2367 times on the Archives of Dermatology Web site.

Back to top
Article Information

Contact Dr Hamzavi at the Department of Dermatology, Center for Multicultural Dermatology, Henry Ford Hospital, 3031 W Grand Blvd, Ste 800, Detroit, MI 48202 (ihamzav1@hfhs.org).

References
1.
Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa [published ahead of print December 19, 2011].  Arch DermatolPubMedArticle
2.
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.  J Am Acad Dermatol. 2010;62(2):205-217PubMedArticle
×